Floatz logo

Vgn-R08B

Parkinson Disease (PD)

Shanghai Vitalgen BioPharma Co., Ltd.gene_therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

255 Active assets in the Parkinson Disease (PD) cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Pardoprunox
Abbott Products
Phase 3BBB
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Istradefylline
Georgetown University
Phase 4BBB

View all 50 →

Same molecule, other indications

Vgn-R08B is also rated in:

Gaucher Disease Type 3Dormant
CCC
Indicative ·
48 / 100
View asset →
Gaucher disease type IIDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →